Diabetes, Immunity and Immunization

STAT+: In small study, weight loss drug boosts immune cells that help fight cancer

STAT

MAY 10, 2023

Prior research has shown that people with obesity have deficiencies in their “natural killer” cells, or NK cells — immune cells that help in combating cancer.

Immunity

Sanofi to acquire Provention Bio, adding to portfolio TZIELD for type diabetes (T1D)

LifeProNow

MARCH 13, 2023

-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9

Diabetes

STAT+: Pharmalittle: New medication appears to stave off type 1 diabetes; CRISPR pioneer founds another startup

STAT

FEBRUARY 16, 2023

Here’s the latest, and do keep in touch … A new medication appears to be helping stave off the development of type 1 diabetes , Nature writes. Approved last November in the United States, it’s also the first drug proven to delay the onset of an autoimmune disorder.

Diabetes

STAT+: Brigham creates institute focused on immunology with record $100 million gift

STAT

MAY 10, 2023

The institute will be led by Brigham immunologist and principal investigator Vijay Kuchroo, who will lead teams dedicated to studying chronic inflammation and discovering drugs for conditions associated with it, such as food allergies and type 1 diabetes. Continue to STAT+ to read the full story…

Immunity

Immunity Immunization Hospitals Diabetes

Vertex pays CRISPR to use its gene editing tech for diabetes drugs

BioPharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Diabetes

STAT+: Flagship Pioneering launches Quotient, a new biotech, in two countries

STAT

NOVEMBER 21, 2023

Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes. Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age.

Diabetes

FDA approves first drug to delay type 1 diabetes

European Pharmaceutical Review

NOVEMBER 18, 2022

Tzield (teplizumab-mzwv), the first drug to help prolong the onset of stage 3 type 1 diabetes in adults and children over eight years old with stage 2 type 1 diabetes, has been approved by the US Food and Drug Administration (FDA). The drug binds to certain immune system cells and delays progression to stage 3 type 1 diabetes.

Diabetes

Lonza and Vertex to partner to manufacture diabetes cell therapies

European Pharmaceutical Review

JUNE 27, 2023

Lonza and Vertex Pharmaceuticals Incorporated have agreed to collaborate to support the manufacture of Vertex’s Type 1 diabetes cell therapy portfolio. It is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection.

Diabetes

Common drug could facilitate “huge step-change” in managing type 1 diabetes

European Pharmaceutical Review

DECEMBER 7, 2023

Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. 

Diabetes

Gene-edited cell replacement therapy for diabetes set to enter the clinic

Outsourcing Pharma

NOVEMBER 16, 2021

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Diabetes

Chikungunya vaccine approved for select groups by CDC advisory panel

STAT

FEBRUARY 28, 2024

vaccination policy when Mandy Cohen, director of the Centers for Disease Control and Prevention, signs off on the recommendation from the Advisory Group on Immunization Practices. Babies infected around the time of birth, adults 65 and older and people with heart disease, diabetes or high blood pressure are at higher risk of severe disease.

Vaccines

FDA fast tracks type 1 diabetes cell therapy from Vertex

pharmaphorum

MARCH 11, 2021

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy for diabetes. . The aim is to replace the pancreatic tissue that is damaged by the autoimmune reaction that underlies type 1 diabetes.

Diabetes

Vertex buys diabetes cell therapy rival ViaCyte for $320m

pharmaphorum

JULY 11, 2022

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The post Vertex buys diabetes cell therapy rival ViaCyte for $320m appeared first on.

Diabetes

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.

Diabetes

Study finds air pollution lowers Covid vaccine response

Express Pharma

APRIL 7, 2023

The findings, published in the journal Environmental Health Perspectives , provide further evidence on the adverse effects of air pollution on the immune system. However, the role of long-term exposure to air pollution on hybrid immunity (infection plus vaccination) deserves further investigation, they added.

Vaccines

Vaccines Immunity Immunization Diabetes

Market Your Pharmacy with a 2023 Health Awareness Calendar

Digital Pharmacist

JANUARY 16, 2023

From cancer prevention to diabetes awareness, these events help bring communities together. World Immunization Week: April 24-30. National Immunization Awareness Month. National Diabetes Month. World Immunization Week | Post a flyer and share a list on social media of your vaccination offerings. . UV Safety Month.

Immunity

Immunity Immunization Vaccines Diabetes

Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition

pharmaphorum

AUGUST 17, 2020

Phase 3 development in the bleeding disease thrombocytopenia is expected to begin by the end of the year as long as COVID-19 does not impact on trials and there is also an ongoing phase 2 development programme in various other immune diseases.

Immunity

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes

Diabetes Labelling Immunity Immunization

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes

Diabetes Labelling Immunity Immunization

Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bn

pharmaphorum

JANUARY 11, 2021

Cambridge-based Kymab is one of several rising stars on the UK biotech scene, with technology that uses transgenic mice to develop antibodies optimised for the human immune system. KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the process that activates the immune system.

Immunity

Immunity Immunization Diabetes Vaccines

Zoster-Associated Pain Reduced With Effective Intervention Measures

Pharmacy Times

DECEMBER 20, 2022

Associated postherpetic neuralgia risk factors are history of diabetes mellitus, age, and immune-related disease.

Diabetes

A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked.

NY Times

NOVEMBER 27, 2021

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Diabetes

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

pharmaphorum

JUNE 1, 2021

Novo Nordisk – which is already active in stem cell therapies with a candidate in early development for type 1 diabetes – is on the hook for up to $598 million in total licensing and milestone payments plus royalties on sales if HS-001 reaches the market.

Immunity

GSK launches shingles vaccine, Shingrix in India

Express Pharma

APRIL 24, 2023

Adults above 50 years of age and those suffering from chronic conditions such as diabetes, heart disease and kidney diseases are at an increased risk of developing shingles because of weakened immunity. Vaccination is the only effective preventive option.”

Vaccines

AZ halts development of Beta variant COVID-19 vaccine

pharmaphorum

FEBRUARY 10, 2022

In its annual results statement, AZ said that it took the decision on the back of data showing that a third dose of Vaxzevria increased the immune response to new variants, including Omicron which is currently driving new COVID-19 cases around the world. ” Vaxzevria added almost $4 billion to its revenues last year, including $1.8

Vaccines

Vaccines Immunity Immunization Diabetes

BioMed X and Sanofi partner to leverage AI for drug development

Pharmaceutical Technology

OCTOBER 25, 2022

As proof-of-concept (PoC), chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD) will be the focus areas of the preliminary model. For the project, deep datasets and capabilities of Sanofi will be leveraged to potentially transform the practice of medicine using digital data and AI.

Drug Development

Drug Development Diabetes Immunity Immunization

AI tool may help doctors select best drugs for COVID patients

pharmaphorum

NOVEMBER 12, 2021

It also takes into account existing and chronic health factors such as diabetes, obesity, and conditions that affect the immune system can play a big role in risk factors related to COVID-19.

Diabetes

Top Clinical Services for Boosting Your Pharmacy’s Revenue

Digital Pharmacist

JULY 11, 2023

Immunizations & Vaccinations Independent pharmacies are ideally positioned to provide convenient immunization services to their communities. Chronic Disease Management Independent pharmacies can play a crucial role in managing chronic diseases such as diabetes, hypertension, and asthma.

Independent Pharmacies

Independent Pharmacies Medication Therapy Management (MTM) Compounding Scheduling Appointments

Quell Therapeutics and AstraZeneca partner on Treg cell therapies

Pharmaceutical Technology

JUNE 12, 2023

The partnership will use Quell’s toolbox of Treg cell engineering modules, which includes the Foxp3 phenotype lock, to create autologous multi-modular Treg cell therapy candidates to treat Type 1 diabetes (T1D) and inflammatory bowel disease (IBD).

Immunity

Recap of the NHC’s Annual Membership Meeting and Luncheon & New Board Announced

Putting Patients First Blog

DECEMBER 18, 2023

Schubert , President & CEO, Society for Women’s Health Research Michael Ybarra , MD , Chief Medical Officer, PhRMA Sunita Mishra , MD , Chief Medical Officer, Amazin Health Services Michele M.

Diabetes

Diabetes Communication Immunity Immunization

Latest WHO Covid-19 vaccine guidance may decrease future demand

Pharmaceutical Technology

APRIL 3, 2023

The latest guidance applies to the current phase of the pandemic and reflects the impact of the Omicron variant, which has led to high levels of immunity in all age groups through both vaccination efforts and infections across the globe.

Vaccines

ZNA-1041 by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval

Pharmaceutical Technology

MAY 31, 2023

It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions.

Diabetes

Diabetes Immunity Immunization Hospitals

Update on Recent International Biosimilar Approvals

Big Molecule Watch

SEPTEMBER 25, 2023

YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

Two new drugs added to WHO list of COVID-19 therapies

pharmaphorum

JANUARY 17, 2022

It prevents the overstimulation of the immune system and is said to improve survival and reduce the need for ventilation in covid-19 patients, with no observed increase in adverse effects. Baricitinib, administered with corticosteroids, was strongly recommended as a treatment for patients with severe or critical illness.

Hospitals

Hospitals Diabetes Immunity Immunization

PharmaShots Weekly Snapshots (March 20 - 24, 2023)

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes

Diabetes Immunity Immunization Biosimilars

What is Stiff-Person Syndrome?

Board Vitals - Pharmacist

DECEMBER 9, 2022

Patients with SPS often have another autoimmune disease, including type 1 diabetes, pernicious anemia, thyroiditis, vitiligo, and certain types of cancers. Intravenous immune globulin (IVIG) C. Most people who live with SPS start experiencing symptoms between the ages of 30 and 60. Is there a cure for Stiff-Person Syndrome?

Immunity

Celebrating National Pharmacist Day

Board Vitals - Pharmacist

JANUARY 11, 2024

Complete a state-mandated number of hours as a pharmacy intern Some pharmacists become certified in specialty areas such as immunization, diabetes education, nutrition or oncology. Licensing boards for these specialties vary.

Retail Drug Stores

Retail Drug Stores Hospitals Doctor of Pharmacy Dosage

Sleep

RX Note

APRIL 21, 2023

Lack of sleep can increase the risk of chronic diseases , such as coronary heart disease, hypertension, stroke, obesity, diabetes as well as weakened immune system. Mental Health Sleep helps with learning and the formation of long-term memories.

Diabetes

Understanding the microbiome as an ‘overlooked critical organ’

pharmaphorum

APRIL 26, 2022

As more research has been conducted, closer and unexpected links have been found between the microbiome of the gut, as one example, and other areas of the body, such as brain health and the immune system. Compelling advantages.

Immunity

Immunity Immunization Diabetes Drug Development

HepaStem seems most promising pipeline agent for decompensated cirrhosis due to NASH: GlobalData

Express Pharma

SEPTEMBER 12, 2023

tumor formation, immune reactions, and therapy failure). tumor formation, immune reactions, and therapy failure). As such, it is unsurprising that a stem cell therapy is being considered for the treatment of DC due to NASH.

Diabetes

Prevent Blindness President & CEO Jeff Todd to Lead 2024 National Health Council Board of Directors

Putting Patients First Blog

DECEMBER 12, 2023

Seven new members are joining the 2024 NHC Board of Directors: Charles Henderson , Chief Executive Officer, American Diabetes Association; Louise Vetter , President & Chief Executive Officer, Huntington’s Disease Society of America; Jorey Berry , President & Chief Executive Officer, Immune Deficiency Foundation; Kathryn G.

Diabetes

NIH abandons convalescent plasma trial in mild COVID

pharmaphorum

MARCH 3, 2021

Convalescent plasma taken from recovered COVID-19 patients is laden with antibodies against SARS-CoV-2, and the hope was this could be used to confer a form of passive immunity to individuals still battling the infection. Last year, the PLACID trial found no benefit of the therapy in patients hospitalised with moderate COVID-19.

Immunity

Immunity Immunization Diabetes Hospitals

US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults

Express Pharma

MAY 3, 2023

Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at increased risk of severe RSV illness and drive the majority of RSV hospitalisations. RSV is a common, contagious virus that can lead to potentially serious respiratory illness.

Vaccines